



USA-India Chamber of Commerce

Accelerating USA-India Trade & Investments

USA-India Chamber of Commerce

presents its annual

US-India BioPharma & Healthcare Summit

Thursday, June 23, 2011: 10-00 AM to 7-30 PM
President's Ballroom, Hyatt Cambridge, Massachusetts, USA

Panel Discussions Covering

- Drug Discovery and Collaborative Research
- R&D Models: Lessons Learned for BioPharma
- Industry-Academic Partnerships
- Clinical Research – Opportunities and Challenges
- Best Practices for Making Alliances Work
- Restructuring R&D to Maximize Productivity & Innovation
- Diabetes- Science, Research Trends and Investor Perspective
- Funding innovation, Cross Border Investments and M&A trends in the BioPharma & Healthcare
- Presentation of Position Paper by Boston Consulting Group

Pre Summit Strategy sessions (by invitation only): External Research Strategies
Clinical Research/Industry-Academic Partnerships

Networking Tea Breaks, Hosted Lunch, Cocktails & High Power Networking Reception

Advisory Board



Dr. Barry Bloom
Professor and past Dean
Harvard School of Public Health



D.S. Brar
Chairman
GVK Biosciences



Dr. William Chin
Executive Dean of Research
Harvard Medical School



Dr. Victor Dzau
Chancellor of Health Affairs
Duke University



Dr. Nirmal K. Ganguly
Chairman JIPMER &
Ex. Director General, ICMR




Dr. Ansbert Gadick
Founder & Managing Partner
MPM Capital



Dr. Ivan Gergel
Executive Vice President R&D
Endo Pharmaceuticals



Dr. David Lacey
Sr. Vice President &
Head of Research, Amgen



Dr. John Leonard
Senior Vice President
Pharma R&D, Abbott



Dr. Martin Mackay
President Global R&D
AstraZeneca



Joel Marcus
Chairman & CEO
Alexandria



Kiran Mazumdar-Shaw
Chairman
Biocon




Peter Mueller, PhD
Executive Vice President R&D
Vertex Pharmaceuticals



Dr. Michael Rosenblatt
Executive Vice President and CMO
Merck & Co.



Helmut M. Schühler, PhD
Managing Partner
TVM Capital



Dr. Allen Spiegel
Dean, Albert Einstein
College of Medicine



Dr. Paul Stoffels
Worldwide Chairman
Pharmaceuticals Group
Johnson & Johnson




Mervyn Turner, PhD
Chief Strategy Officer
Merck & Co



Raju Kucherlapati, PhD
Department of Genetics
Harvard Medical School



Dr. Inder Verma
Irwin & Joan Jacobs Chair in
Exemplary Life Science
The Salk Institute



Shri Pawan Kumar Bansal
Minister of Parliamentary Affairs, Science & Technology and Earth Sciences

Biotechnology has emerged as an important area of research and enterprise in India. The Government of India has been very supportive of this sector and has encouraged innovation and entrepreneurship through novel and innovative schemes, both for the public and private sector. The USA-India Chamber of Commerce has been playing an active role in the development of business ties between India and the US. I am sure the Summit will result in developing stronger ties between US and India in the field of Biotechnology.



Shri Srikant Kumar Jena
Minister of State
Ministry of Chemicals & Fertilizers

Major global pharma companies are looking at India seriously with a huge market potential. I hope the leadership of these companies will also look at India as a strategic partner for their global drug discovery and development initiatives. We have seen the USAIC's annual Summit making immense contributions by bringing the key global BioPharma industry and Indian stakeholders together. I look forward to receiving recommendations deliberated at the annual Summit.



Dr. M.K. Bhan
Secretary to the Government of India, Department of Biotechnology
and Advisory Board Member of the US-India BioPharma & Healthcare Summit

Hon'ble Prime Minister of India has declared this as a decade of innovation. Global partnerships particularly with leadership countries such as United States are a key component of establishing global best practices. We fully recognize that an educated and effective human resource, physical infrastructure, sustained intellectual property policy and practice, science based and efficient regulation, hassle free business and trade practices are absolutely essential to fulfill the national vision of a quality innovation system.



Karun Rishi
President, USA-India Chamber of Commerce

USA-India Chamber of Commerce has created a vibrant purpose driven innovation ecosystem bringing together all stakeholders: healthcare and life sciences executives, investors, academia and policy makers. Our annual Summit has become THE BioPharma event in the world to learn, share, deliberate, network and benefit for senior executives focused on Drug Discovery & Development, Licensing, Clinical Research, Healthcare, Innovation, M&A, Deal Flow and Emerging Markets. I encourage the active participation of all stakeholders who share our purpose of working together for an innovation driven healthier world.



Hari S Bhartia
Co - Chairman & MD, Jubilant Life Sciences and Advisory Board Member of the US-India BioPharma & Healthcare Summit

For the last five years, I have observed the annual US-India BioPharma & Healthcare Summit play a significant role in forging partnerships between the global BioPharma and Indian companies. USAIC has been able to involve and engage Global BioPharma R&D leaders and key stakeholders to foster innovation. These interactions have led to innovative business ideas, new partnerships and business.



Dr. Mikael Dolsten
President, Worldwide R&D, Pfizer and Advisory Board Member of the US-India BioPharma & Healthcare Summit

Biopharma and biotech companies have a strong interest in the continued growth of India's innovative drug research industry – to improve public health in India and the world. Pfizer has a global network of academic alliances and strategic partnerships, including collaborations with several Indian Biopharma companies and CROs, to accelerate our delivery of differentiated medicines. This summit, organized by the USA-India Chamber of Commerce, by connecting companies with high quality drug designers and developers in India, is valuable to the industry and to patients.



K.V. Subramaniam
President & CEO, Reliance Life Sciences and Advisory Board Member of the US-India BioPharma & Healthcare Summit

The innovation-driven ecosystem fostered by the USA-India Chamber of Commerce has led to meaningful research and technology partnerships between global and Indian companies. I have been involved with this platform for the last few years and it is a great feeling to see it evolve as the Summit of Choice for global research and technology leaders and investors.



Dr. Naresh Trehan
Chairman Medanta - The Medicity and Advisory Board Member of the US-India BioPharma & Healthcare Summit

Global partnerships are vital for the future of medicine. India can be a key partner in safe and rapid development of therapies targeted at significant health problems. These partnerships can produce research that will enable development of drugs and devices to improve health around the world.

LEARN SHARE NETWORK BENEFIT

LEARN SHARE NETWORK BENEFIT